279 related articles for article (PubMed ID: 8113980)
1. Identification of mechanisms and sites of actions of mu and delta opioid receptor activation in the canine intestine.
Fox-Threlkeld JE; Daniel EE; Christinck F; Hruby VJ; Cipris S; Woskowska Z
J Pharmacol Exp Ther; 1994 Feb; 268(2):689-700. PubMed ID: 8113980
[TBL] [Abstract][Full Text] [Related]
2. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
3. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells.
Zadina JE; Harrison LM; Ge LJ; Kastin AJ; Chang SL
J Pharmacol Exp Ther; 1994 Sep; 270(3):1086-96. PubMed ID: 7932156
[TBL] [Abstract][Full Text] [Related]
5. Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions.
Shook JE; Pelton JT; Lemcke PK; Porreca F; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1987 Jul; 242(1):1-7. PubMed ID: 2886635
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic evaluation of a cyclic somatostatin analog with antagonist activity at mu opioid receptors in vitro.
Shook JE; Pelton JT; Wire WS; Hirning LD; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1987 Mar; 240(3):772-7. PubMed ID: 2882015
[TBL] [Abstract][Full Text] [Related]
7. Differential modulation by [D-Pen2, D-Pen5]enkephalin and dynorphin A-(1-17) of the inhibitory bladder motility effects of selected mu agonists in vivo.
Sheldon RJ; Nunan L; Porreca F
J Pharmacol Exp Ther; 1989 May; 249(2):462-9. PubMed ID: 2566676
[TBL] [Abstract][Full Text] [Related]
8. Peptide opioid antagonist separates peripheral and central opioid antitransit effects.
Shook JE; Pelton JT; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1987 Nov; 243(2):492-500. PubMed ID: 2824748
[TBL] [Abstract][Full Text] [Related]
9. Continuous intrathecal opioid analgesia: tolerance and cross-tolerance of mu and delta spinal opioid receptors.
Russell RD; Leslie JB; Su YF; Watkins WD; Chang KJ
J Pharmacol Exp Ther; 1987 Jan; 240(1):150-8. PubMed ID: 3027302
[TBL] [Abstract][Full Text] [Related]
10. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.
Horan PJ; Wild KD; Kazmierski WM; Ferguson R; Hruby VJ; Weber SJ; Davis TP; Fang L; Knapp RJ; Yamamura HI
Eur J Pharmacol; 1993 Mar; 233(1):53-62. PubMed ID: 8386089
[TBL] [Abstract][Full Text] [Related]
11. Mu and delta opioid receptors inhibit serotonin release in rat hippocampus.
Passarelli F; Costa T
J Pharmacol Exp Ther; 1989 Jan; 248(1):299-305. PubMed ID: 2536429
[TBL] [Abstract][Full Text] [Related]
12. Bidirectional effects of endogenous opioid peptides on endothelin release rates in porcine aortic endothelial cell culture: mediation by delta opioid receptor and opioid receptor antagonist-insensitive mechanisms.
Arendt RM; Schmoeckel M; Wilbert-Lampen U; Plasse A; Heucke L; Werdan K
J Pharmacol Exp Ther; 1995 Jan; 272(1):1-7. PubMed ID: 7815321
[TBL] [Abstract][Full Text] [Related]
13. Opioid profiles of Cys2-containing enkephalin analogues.
Pencheva N; Milanov P; Vezenkov L; Pajpanova T; Naydenova E
Eur J Pharmacol; 2004 Sep; 498(1-3):249-56. PubMed ID: 15364002
[TBL] [Abstract][Full Text] [Related]
14. Role of mu and delta receptors in the supraspinal and spinal analgesic effects of [D-Pen2, D-Pen5]enkephalin in the mouse.
Porreca F; Heyman JS; Mosberg HI; Omnaas JR; Vaught JL
J Pharmacol Exp Ther; 1987 May; 241(2):393-400. PubMed ID: 3033214
[TBL] [Abstract][Full Text] [Related]
15. Mu and delta opioid receptor desensitization in undifferentiated human neuroblastoma SHSY5Y cells.
Prather PL; Tsai AW; Law PY
J Pharmacol Exp Ther; 1994 Jul; 270(1):177-84. PubMed ID: 8035314
[TBL] [Abstract][Full Text] [Related]
16. Effect of ambient temperature on the ability of mu-, kappa- and delta-selective opioid agonists to modulate thermoregulatory mechanisms in the rat.
Handler CM; Piliero TC; Geller EB; Adler MW
J Pharmacol Exp Ther; 1994 Feb; 268(2):847-55. PubMed ID: 8113997
[TBL] [Abstract][Full Text] [Related]
17. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
Kramer TH; Shook JE; Kazmierski W; Ayres EA; Wire WS; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1989 May; 249(2):544-51. PubMed ID: 2566679
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological evidence for a 7-benzylidenenaltrexone-preferring opioid receptor mediating the inhibitory actions of peptidic delta- and mu-opioid agonists on neurogenic ion transport in porcine ileal mucosa.
Poonyachoti S; Portoghese PS; Brown DR
J Pharmacol Exp Ther; 2001 May; 297(2):672-9. PubMed ID: 11303057
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action of cholecystokinin in the canine gastrointestinal tract: role of vasoactive intestinal peptide and nitric oxide.
Vergara P; Woskowska Z; Cipris S; Fox-Threlkeld JE; Daniel EE
J Pharmacol Exp Ther; 1996 Oct; 279(1):306-16. PubMed ID: 8859008
[TBL] [Abstract][Full Text] [Related]
20. Influence of nitric oxide and vasoactive intestinal peptide on the spontaneous and triggered electrical and mechanical activities of the canine ileum.
Cayabyab FS; Jiménez M; Vergara P; deBruin H; Daniel EE
Can J Physiol Pharmacol; 1997 May; 75(5):383-97. PubMed ID: 9250372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
